

Uterine contractility in response to different prostaglandins: results from extracorporeally perfused non-pregnant swine uteri

Andreas Mueller¹, Theodoros Maltaris, Joern Siemer, Helge Binder, Inge Hoffmann, Matthias W.Beckmann and Ralf Dittrich

Department of Obstetrics and Gynaecology, Erlangen University Hospital, Erlangen, Germany

¹To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, Erlangen University Hospital, Universitaetsstrasse 21–23, 91054 Erlangen, Germany. E-mail: andreas.mueller@gyn.imed.uni-erlangen.de

BACKGROUND: Prostaglandins (PGs) are important stimulators of uterine contractility. Limited data are available at present on the effects of different PGs on uterine contractility, measured using intraluminal pressure changes in the complete uterus. The goal of this study was to assess dynamic changes in uterine contractility and peristalsis in response to PGs in comparison with the effects of oxytocin administration. **METHODS:** An extracorporeal perfusion model of swine uteri was used, which keeps the uterus in a functional condition, and is appropriate for the study of physiological questions. Oxytocin- and PG-induced uterine contractility and peristalsis were assessed using an intra-uterine double-chip microcatheter. **RESULTS:** A dose-dependent increase in intrauterine pressure (IUP) in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$) was observed after the administration of $\text{PGF}_{2\alpha}$ and oxytocin, which reached a plateau after further stimulation. A dose-dependent increase in IUP in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$) was also observed after the administration of PGE_1 and PGE_2 , with a plateau in IUP in the middle-concentration range and a decrease in the course of further stimulation. PGE_2 caused significantly more contractions starting in the corpus uteri and moving to the isthmus uteri ($P = 0.008$). The direction of most contractions caused by PGE_1 , PGE_2 and oxytocin differed from that of $\text{PGF}_{2\alpha}$. **CONCLUSIONS:** This study demonstrates that the PGs tested modulate contractility in non-pregnant swine uteri in a characteristic way, resulting in different contractility patterns.

Key words: animal model/peristalsis/prostaglandin/sperm transport/uterine contractility

Introduction

Adequate uterine contractility and intact uterotubal transport function are required for the transport of semen and gametes and for successful embryo implantation, whereas inadequate uterine contractility may lead to ectopic pregnancies, miscarriages, retrograde bleeding and endometriosis (Bulletti *et al.*, 2001, 2002; Kissler *et al.*, 2004a; Leyendecker *et al.*, 2004; Bulletti and de Ziegler, 2005).

Oxytocin levels fluctuate throughout the menstrual cycle and correlate with genital lubrication and sexual arousal in women (Carmichael *et al.*, 1987; Murphy *et al.*, 1990; Carter, 1992; Gimpl and Fahrenholz, 2001; Argiolas and Melis, 2003); they are therefore believed to play a role in the peripheral activation of sexual function (Evans *et al.*, 2003; Benoussaidh *et al.*, 2004; Salonia *et al.*, 2005). Oxytocin is used clinically to induce labour at term, as one of the most potent uterotonic agents, and exerts a wide spectrum of central and peripheral physiological effects (McNeilly *et al.*, 1983; Carmichael *et al.*, 1987; Murphy *et al.*, 1990; Carter, 1992; Russell and Leng,

1998; Gimpl and Fahrenholz, 2001; Thornton *et al.*, 2001; Argiolas and Melis, 2003; Caba *et al.*, 2003; Woodcock *et al.*, 2004). On the contrary, prostaglandins (PGs) are known to play a key role in the maintenance of human pregnancy and the onset of labour, whereas their possible role in regulation of uterine contractility in non-pregnant uteri is still enigmatic. PGE_1 , in particular, is secreted by the seminal vesicle and prostate gland and is present in human seminal plasma (Bygdeman and Samuelsson, 1967; Robertson, 2005). In addition, the endometrium itself is able to generate different PGs, which may play a significant role in placentation and in regulating the lifespan of the corpus luteum (Herath *et al.*, 2006; Waclawik *et al.*, 2006). In addition to steroids and oxytocin, PGs are also believed to modulate myometrial contractility in a characteristic way not only at the time of labour but also at the time of human reproduction (Hertelendy and Zakar, 2004). In a study of myometrial PG receptor expression, a region-dependent, heterogeneous distribution of contractile and relaxant prostanoid receptors and cyclooxygenase was reported in the non-pregnant

porcine myometrium (Cao *et al.*, 2005). In pregnancy, it is known that the regulation of uterine contractility involves PG interactions (Hurd *et al.*, 2005; Ziganshin *et al.*, 2005). Hirst *et al.* (2005) have reported that it is possible to suppress uterine contractility and delay preterm labour using a novel PGF_{2α} receptor antagonist in sheep. To date, however, only cell-culture experiments using isolated muscle strips have been conducted to record uterine contractility (Palliser *et al.*, 2005). Differences have also been found in the localization and expression of PG receptors in human myometrium during pregnancy (Aistle *et al.*, 2005). To our knowledge, however, uterine contractility caused by different PGs has not previously been examined in an experimental model using the complete uterus.

The original extracorporeal perfusion model of an isolated uterus was first described by Bulletti *et al.* (1986). Previous investigations have validated the feasibility of this perfusion model of isolated uteri for various purposes (Bulletti *et al.*, 1987, 1988a, 1988b; Richter *et al.*, 2000, 2003, 2004, 2006). This perfusion model is able to keep the uterus in a functional condition and is suitable for the study of physiological questions (Bulletti *et al.*, 1993, 2001, 2002). The development of an extracorporeal perfusion model of the swine uterus enabled our group to carry out general assessments of uterine contractility and peristalsis (Dittrich *et al.*, 2003; Maltaris *et al.*, 2005a, 2005b; Mueller *et al.*, 2005, 2006).

The aim of the present study was to monitor uterine contractility in the corpus uteri and the isthmus uteri continuously, to determine intrauterine pressure (IUP) changes and to evaluate the role of PGE₁, PGE₂ and PGF_{2α} in the regulation of uterine contractility in comparison with oxytocin. The advantage of the animal model used is that it makes it possible to test a large number of uteri, similar in size and condition, from young and healthy animals within the reproductive lifespan.

Materials and methods

Swine uterus

Swine (*Sus scrofa domestica*) are widely used in research. The swine uterus is a long bicornuate uterus with a single corpus and a single cervix. The uterine wall has a similar architecture to that in humans and in other domestic animals, with the three classic histological elements of the uterine wall—the endometrium; the myometrium, which consists of clearly oriented smooth-muscle cells; and the perimetrium. The endometrium contains many hundreds of glands in a cross-section of the uterine wall, and the myometrium is clearly differentiated into inner circular and outer longitudinal layers. The Fallopian tubes in the adult female have the same diameter as those in humans. However, they are much longer, and the uterine corpus is also longer in comparison with human uteri. The sow has an estrus cycle of 20–21 days.

Swine uteri were obtained from the local slaughterhouse. They all came from healthy animals aged 5–18 months. Sixty uteri were selected on the basis of their size and overall condition, as well as the condition of the uterine arterial stumps, and randomly assigned to four groups ($n = 15$ in each group) that were comparable with regard to the size, weight, condition and age of the animals and unrelated to phase of the estrus cycle. The mean weight of all the swine uteri was 128 g (range 85.5–162.8 g). Swine uteri are very easily separated from the rest of the body within approximately 2 min, shortly after the animal is killed by electric shock (1.5 A, 400 V, 4 s).

Perfusion system

After catheter placement in the uterine vessels with 16–24-gauge needles (Abbocath-T; Abbott Ireland, Sligo, Ireland), depending on the uterus size, the organ was placed in a controlled temperature perfusion chamber (Karl Lettenbauer, Erlangen, Germany) filled with the perfusion medium. The uterus was then connected bilaterally with two reservoirs containing the perfusion medium (Krebs–Ringer bicarbonate glucose buffer, Sigma, Deisenhofen, Germany). The perfusion medium was oxygenated with carbogen gas (a mixture of 95% oxygen and 5% carbon dioxide) and then forced into the uterine arterial catheters with two roller pumps. The flow rate of the perfusion medium was constantly monitored and kept at 15 ml/min and 100 mmHg.

Vitality parameters

Perfusate samples were taken at 1-h intervals for measurement of pH, PO₂, PCO₂, HCO₃, lactate and oxygen saturation. The perfusate samples were analysed using an i-STAT portable clinical analyzer (Abbott Diagnostics, Abbott Park, IL, USA).

Intrauterine pressure measurement

IUP was recorded using an intrauterine double-chip microcatheter (Urobar 8 DS-F, Raumedic, Muenchberg, Germany) with a distance of 8 cm between the two pressure sensors. One sensor was placed in the isthmus uteri, and the other was placed in the corpus uteri in the swine uterus. The Fallopian tubes and cervix uteri were not closed. The double-chip microcatheter was connected to a Datalogger (MPR1, Raumedic) for continuous monitoring of IUP at both the locations, with the data being transferred to a personal computer.

Induction of uterine contractions

Oxytocin (Syntocinon; Novartis Germany Ltd., Nuremberg, Germany), at increasing dosages of 0.5–10 IU, and PGE₁ (alprostadil, Caverject; Pharmacia, Erlangen, Germany), PGE₂ (dinoprostone, Minprostin E₂; Pharmacia, Erlangen, Germany) and PGF_{2α} (sulprostone, Nalador; Schering, Berlin, Germany), at increasing dosages of 0.5–10 µg, were used to induce contractions of the uterus and were administered every 30 min. All medications were administered as bolus injections through the uterine arterial catheters.

Statistical analysis

A paired *t*-test was used for statistical evaluation of IUP increases during uterine contractions in the isthmus uteri in comparison with that in the corpus uteri for each tested concentration of the test substances, whereas an unpaired *t*-test was used for statistical evaluation of IUP caused by the different test substances. Pressure differences between the different concentrations of test substances were evaluated using analysis of variance for the repeated measurements. In addition, the chi-squared test of independence was used to assess whether uterine contractions started in the isthmus uteri or the corpus uteri. All calculations were performed using the Statistical Program for the Social Sciences (SPSS, version 10.1 for Windows; SPSS, Inc., Chicago, IL, USA). *P* values of less than 0.05 were considered statistically significant.

Results

The experiments were only carried out when it was possible to maintain constant flow rates of the perfusion medium of 15 ml/min through each artery, with an ideal pressure of 100 mmHg, throughout the duration of the experiments. The vitality parameters remained physiological during the first 8 h of perfusion (data not shown; for details, see Dittrich *et al.*, 2003; Maltaris *et al.*,

2005a, 2005b; Mueller *et al.*, 2005). Regularly recurring peristaltic waves, with IUP increases in both the corpus uteri and the isthmus uteri, were achieved in all of the perfused swine uteri and were continuously measured using the intrauterine double-chip catheter described (Mueller *et al.*, 2006). For all groups, IUP changes showed similar values for the amplitude and duration of the uterine contractions. Data for increases in IUP are demonstrated as pooled data (each group contained 15 uteri) with mean values \pm SD.

Oxytocin

In general, a dose-dependent increase in IUP in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$) was observed following oxytocin administration. A plateau in IUP was observable after administration of 5 IU of oxytocin, while no increase of IUP was measured using more than 5 IU of oxytocin. The differences between IUP in the isthmus and that in the corpus uteri were not significant (Figure 1).

Prostaglandins

A dose-dependent increase in IUP in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$) was observed following PGE₁ administration. A plateau in IUP was observable after administration of 4–6 μ g, whereas when higher dosages were used, a decrease in IUP was observed in both the locations. Dosages of 3–6 μ g caused a significantly higher IUP in the isthmus uteri (for 3 μ g, $P = 0.001$; 4 μ g, $P = 0.002$; 5 μ g, $P < 0.001$ and 6 μ g, $P < 0.001$) in comparison with the corpus uteri (Figure 2). After administration of PGE₂, a dose-dependent increase in IUP in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$) was observed. A plateau in IUP was observable after administration of 3–5 μ g, whereas a decrease in IUP in both the locations was seen using higher dosages (Figure 3). Dosages of 3–5 μ g PGE₂ caused a significantly higher increase in IUP in the isthmus uteri (3 μ g, $P = 0.04$; 4 μ g, $P = 0.03$ and 5 μ g, $P = 0.04$) in comparison with that in the corpus uteri, whereas the other concentrations tested caused no significant




Figure 1. Increases in intrauterine pressure (IUP), shown as means and SD after administration of increasing dosages of oxytocin. A dose-dependent increase in IUP was observed in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$), following oxytocin administration.




Figure 2. Increases in intrauterine pressure (IUP), shown as means and SD after administration of increasing dosages of prostaglandin E₁. Dosages of 3–6 μ g caused a significantly higher IUP in the isthmus uteri (for 3 μ g, $P = 0.001$; 4 μ g, $P = 0.002$; 5 μ g, $P < 0.001$ and 6 μ g, $P < 0.001$) in comparison with that in the corpus uteri.




Figure 3. Increases in intrauterine pressure (IUP), shown as means and SD after administration of increasing dosages of prostaglandin E₂ (PGE₂). Dosages of 3–5 μ g PGE₂ caused a significantly higher IUP increase in the isthmus uteri (3 μ g, $P = 0.04$; 4 μ g, $P = 0.03$ and 5 μ g, $P = 0.04$) in comparison with that in the corpus uteri.

differences between the two locations. After administration of PGF_{2 α} , a similar contractility pattern was seen in comparison with oxytocin administration, with a dose-dependent increase in IUP in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$) and with a plateau reached after administration of 5 μ g PGF_{2 α} . No differences were observed in the IUP increase measured in the isthmus uteri in comparison with that in the corpus uteri (Figure 4). The greatest increase in IUP was seen in the isthmus uteri after administration of PGE₁ ($P < 0.001$ versus PGE₂, $P < 0.0001$ versus PGF_{2 α} and $P < 0.0001$ versus oxytocin) followed by PGE₂ ($P < 0.001$ versus PGF_{2 α} and $P < 0.001$ versus oxytocin) at the dosages tested. Both PGE₁ and PGE₂ caused a statistically significantly higher increase in IUP in the isthmus uteri in comparison with that in the corpus uteri, resulting in a cervicofundic pressure gradient.

After administration of oxytocin and PGE₁, most contraction waves were observed to start in the corpus uteri with peristalsis




Figure 4. Increases in intrauterine pressure (IUP), shown as means and SD after administration of increasing dosages of prostaglandin F_{2α} (PGF_{2α}). After administration of PGF_{2α}, a dose-dependent increase in IUP in the isthmus uteri ($P < 0.001$) and the corpus uteri ($P < 0.001$) was observed, reaching a plateau after administration of 5 µg PGF_{2α}.




Figure 5. Number in % of peristaltic waves starting in the corpus uteri (grey bars) and the isthmus uteri (black bars). Each group contains 15 perfused uteri. Uterine contractions starting in the isthmus uteri or the corpus uteri were tested using the chi-squared test of independence. For prostaglandin E₂ (PGE₂), $P = 0.008$ for corpus versus isthmus uteri.

directed towards the isthmus uteri, whereas after administration of PGF_{2α}, most contraction waves were found to start in the isthmus uteri with peristalsis directed towards the corpus uteri, although these differences were not statistically significant. However, administration of PGE₂ resulted in a significant increase in peristalsis starting in the corpus uteri and moving in the direction of the isthmus uteri ($P = 0.008$) (Figure 5).

Discussion

This study investigated the effects of different PGs on the regulation of uterine contractility in extracorporeally perfused non-pregnant swine uteri in comparison with oxytocin. To our knowledge, uterine contractility in response to different PGs is evaluated here for the first time by measuring IUP in different uterine compartments in an experimental model using the complete organ.

During PGF_{2α} administration, the perfused uteri showed a similar contractility pattern in comparison with oxytocin, with

a dose-dependent increase in IUP being measured at both locations and a plateau in IUP being reached at higher dosages. In contrast, PGE₁ and PGE₂ caused significantly higher increases in IUP in the isthmus uteri in comparison with that in the corpus uteri, resulting in a cervicofundic pressure gradient in middle-concentration ranges at the dosages tested, whereas the administration of higher dosages caused relative quiescence in the uterine myometrium, with a decrease in IUP being measured during the further course of stimulation at both the locations. These results suggest that small amounts of PGE₁ and PGE₂ may play an important role in the regulation of contractility in non-pregnant uteri by generating a cervicofundic pressure gradient. PGF_{2α} was not able to generate a pressure gradient between different compartments in non-pregnant uteri.

The periovulatory cervicofundic peristalsis has been described as 'rapid sperm transport' to the side bearing the dominant follicle, which is a precondition for successful reproduction in humans (Kissler *et al.*, 1995, 2004b; Kunz *et al.*, 1996; Wildt *et al.*, 1998). However, during menstruation, contraction waves appear to be directed towards the cervix (Lyons *et al.*, 1991; Fukuda and Fukuda, 1994). The investigation of uterine contractility and its regulation by PGs is of clinical interest not only in obstetrics—for example, to induce labour or to delay birth and prolong pregnancy—but also in gynaecology and reproductive medicine, especially concerning embryo implantation (Bulletti *et al.*, 2005).

Endogenous or exogenous PGs are important uterine stimulators (Hirst *et al.*, 2005). PGs play an important role in the onset and maintenance of labour (Astle *et al.*, 2005). Engstrom *et al.* (2000) have shown that oxytocin treatment down-regulated the uterine contractile response to PGF_{2α}, whereas atosiban (an oxytocin receptor antagonist) did not influence the *in vitro* response to PGF_{2α}. Interactions between PGs and oxytocin have been described; each is able to influence the receptor status of the other and the corresponding myometrial contractile response, because they act by different mechanisms (Carnahan *et al.*, 1996; Franczak *et al.*, 2005). In addition, oxytocin is involved in the regulation of PGF_{2α} secretion during luteolysis and early pregnancy (Franczak *et al.*, 2005). Hirst *et al.* (2005) were able to show that suppression of PGF_{2α} induced myometrial contractility by a specific PGF_{2α} receptor antagonist in pregnant sheep. The inhibition of PG production is associated with fewer gap junctions and decreased levels of the oxytocin receptor in sheep myometrium and endometrium (Garfield *et al.*, 1980; Wu *et al.*, 1999). It has been postulated that the use of a PGF_{2α} receptor antagonist might be the best therapeutic approach for new tocolytic drugs. In general, PG receptors may be able to serve as targets for the development of appropriate medications to delay preterm labour (Hannah, 2000). PGE₁ and PGE₂ are of considerable interest in relation to human reproductive mechanisms and transport functions through the female genital tract, because they are secreted by the seminal vesicle and prostate gland and are present in human seminal plasma (Bygdeman and Samuelsson, 1967; Robertson, 2005). PGs interact with discrete receptors, and different receptors have been identified for each PG on the basis of their different activity profiles and the generation of the second messengers, whereas oxytocin after binding to its

receptors activates the intracellular phosphatidylinositol pathway (Whiteaker *et al.*, 1995; Franczak *et al.*, 2005; Hirst *et al.*, 2005). However, other factors are also involved in the regulation of uterine contractility or are able to modulate it—such as epidermal growth factor, vascular endothelial growth factor and metabolites of PGF_{2α} (Ribeiro *et al.*, 2003; Willenburg *et al.*, 2004; Wijayagunawardane *et al.*, 2005). In addition, linoleic acid and lipopolysaccharide are likely to differentially alter the PG metabolism or uterine responsiveness to oxytocin (Ross *et al.*, 2004; Cheng *et al.*, 2005; Herath *et al.*, 2006). On the contrary, estrogen and progesterone have been found to modulate the production of PGE and PGF in response to lipopolysaccharide (Herath *et al.*, 2006), and ovarian steroids also influence oxytocin and vasopressin secretion from the posterior lobe of the pituitary gland (Bossmar *et al.*, 1995b). Oxytocin produced by the posterior lobe of the pituitary gland or locally in the uterus appears to be involved in the initiation of labour, whereas vasopressin is believed to play an important role in the uterine hyperactivity occurring in primary dysmenorrhoea (Ekström *et al.*, 1992; Bossmar *et al.*, 1994; Akerlund *et al.*, 1995; Bossmar *et al.*, 1995a). Although PGE and PGF receptor expression and myometrial sensitivity in different parts of the uterus and myometrium have been described in pregnancy and during labour, there is still a lack of comparable data for the non-pregnant uterus (Astle *et al.*, 2005). Activation of the PGF receptor strongly stimulates the myometrium, whereas stimulation of the PGE receptor may lead to contraction or relaxation, depending on the receptor subtype expression (Palliser *et al.*, 2005). Cao *et al.* (2005) described a heterogeneous distribution of contractile or relaxant prostanoid receptors in the non-pregnant porcine myometrium. However, results observed in animal models are not of course generally transferable directly to humans.

In summary, administration of PGF_{2α} showed a contractility pattern similar to the effects seen after oxytocin administration. However, administration of PGE₁ and PGE₂ induced completely different contractility patterns. The role of different PG antagonists or cyclooxygenase inhibitors (e.g. indomethacin) can be investigated also using the experimental model described here. Furthermore, different PG application intervals or a co-treatment with estrogens or progesterone will be a goal of further studies.

Acknowledgement

Research for this study was supported by the ELAN Fund of the University of Erlangen–Nuremberg.

References

- Akerlund M, Melin P and Maggi M (1995) Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. *Adv Exp Med Biol* 395,595–600.
- Argiolas A and Melis MR (2003) The neurophysiology of the sexual cycle. *J Endocrinol Invest* 26 (Suppl. 3),20–22.
- Astle S, Thornton S and Slater DM (2005) Identification and localization of prostaglandin E₂ receptors in upper and lower segment human myometrium during pregnancy. *Mol Hum Reprod* 11,279–287.
- Benoussaidh A, Maurin Y and Rampin O (2004) Spinal effects of oxytocin on uterine motility in anesthetized rats. *Am J Physiol Regul Integr Comp Physiol* 287,R446–R453.
- Bossmar T, Akerlund M, Fantoni G, Szamatowicz J, Melin P and Maggi M (1994) Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of the oxytocin antagonist atosiban. *Am J Obstet Gynecol* 171,1634–1642.
- Bossmar T, Akerlund M, Szamatowicz J, Laudanski T, Fantoni G and Maggi M (1995a) Receptor-mediated uterine effects of vasopressin and oxytocin in non-pregnant women. *Br J Obstet Gynaecol* 102,907–912.
- Bossmar T, Forsling M and Akerlund M (1995b) Circulating oxytocin and vasopressin is influenced by ovarian steroid replacement in women. *Acta Obstet Gynecol Scand* 74,544–548.
- Bulletti C and de Ziegler D (2005) Uterine contractility and embryo implantation. *Curr Opin Obstet Gynecol* 17,265–276.
- Bulletti C, Jasonni VM, Lubicz S, Flamigni C and Gurdipide E (1986) Extracorporeal perfusion of the human uterus. *Am J Obstet Gynecol* 154,683–688.
- Bulletti C, Jasonni VM, Martinelli G, Covoni E, Tabanelli S, Ciotti PM and Flamigni C (1987) A 48-hour preservation of an isolated human uterus: endometrial responses to sex steroids. *Fertil Steril* 47,122–129.
- Bulletti C, Jasonni VM, Tabanelli S, Gianaroli L, Ciotti PM, Ferraretti AP and Flamigni C (1988a) Early human pregnancy *in vitro* utilizing an artificially perfused uterus. *Fertil Steril* 49,991–996.
- Bulletti C, Jasonni VM, Ciotti PM, Tabanelli S, Naldi S and Flamigni C (1988b) Extraction of estrogens by human perfused uterus. Effects of membrane permeability and binding by serum proteins on differential influx into endometrium and myometrium. *Am J Obstet Gynecol* 159,509–515.
- Bulletti C, Prefetto RA, Bazzocchi G, Romero R, Mimmi P, Polli V, Lanfranchi GA, Labate AM and Flamigni C (1993) Electromechanical activities of human uteri during extra-corporeal perfusion with ovarian steroids. *Hum Reprod* 8,1558–1563.
- Bulletti C, DeZiegler D, Stefanetti M, Cicinelli E, Pelosi E and Flamigni C (2001) Endometriosis: absence of recurrence in patients after endometrial ablation. *Hum Reprod* 16,2676–2679.
- Bulletti C, DeZiegler D, Polli V, Del Ferro E, Palini S and Flamigni C (2002) Characteristics of uterine contractility during menses in women with mild to moderate endometriosis. *Fertil Steril* 77,1156–1161.
- Bulletti C, Flamigni C and de Ziegler D (2005) Implantation markers and endometriosis. *Reprod Biomed Online* 11,464–468.
- Bygdeman M and Samuelsson B (1967) Prostaglandins in human seminal plasma and their effects on human myometrium. *Int J Fertil* 12 (1 Pt 1),17–20.
- Caba M, Rovirosa MJ and Silver R (2003) Suckling and genital stroking induces Fos expression in hypothalamic oxytocinergic neurons of rabbit pups. *Brain Res Dev Brain Res* 143,119–128.
- Cao J, Yosida M, Kitazawa T and Taneike T (2005) Uterine region-dependent differences in responsiveness to prostaglandins in the non-pregnant porcine myometrium. *Prostaglandins Other Lipid Mediat* 75,105–122.
- Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W and Davidson JM (1987) Plasma oxytocin increase in the human sexual response. *J Clin Endocrinol Metab* 64,27–31.
- Carnahan KG, Prince BC and Mirando MA (1996) Exogenous oxytocin stimulates uterine secretion of prostaglandin F₂ alpha in cyclic and early pregnant swine. *Biol Reprod* 55,838–843.
- Carter CS (1992) Oxytocin and sexual behavior. *Neurosci Biobehav Rev* 16,131–144.
- Cheng Z, Abayasekara DR and Wathes DC (2005) The effect of supplementation with n-6 polyunsaturated fatty acids on 1-, 2- and 3-series prostaglandin F production by ovine uterine epithelial cells. *Biochim Biophys Acta* 1736,128–135.
- Dittrich R, Maltaris T, Mueller A, Dragonas C, Scalera F and Beckmann MW (2003) The extracorporeal perfusion of swine uterus as an experimental model: the effect of oxytocic drugs. *Horm Metab Res* 35,517–522.
- Ekström P, Akerlund M, Forsling M, Kindahl H, Laudanski T and Mrugacz G (1992) Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment – effect on uterine contractility. *Br J Obstet Gynaecol* 99,680–684.
- Engstrom T, Bratholm P, Christensen NJ and Vilhardt H (2000) Effect of oxytocin receptor blockade on rat myometrial responsiveness to prostaglandin F(2) (alpha). *Biol Reprod* 63,1443–1449.
- Evans JJ, Reid RA, Wakeman SA, Croft LB and Benny PS (2003) Evidence that oxytocin is a physiological component of LH regulation in non-pregnant women. *Hum Reprod* 18,1428–1431.
- Franczak A, Ciereszko R and Kotwica G (2005) Oxytocin (OT) action in uterine tissues of cyclic and early pregnant gilts: OT receptors concentration, prostaglandin F(2)alpha secretion, and phosphoinositide hydrolysis. *Anim Reprod Sci* 88,325–339.

- Fukuda M and Fukuda K (1994) Uterine endometrial cavity movement and cervical mucus. *Hum Reprod* 9,1013–1016.
- Garfield RE, Merrett D and Grover AK (1980) Gap junction formation and regulation in myometrium. *Am J Physiol* 239,C217–C228.
- Gimpl G and Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. *Physiol Rev* 81,629–683.
- Hannah ME (2000) Search for the best tocolytic for preterm labour. *Lancet* 356,699–700.
- Herath S, Fischer DP, Werling D, Williams EJ, Lilly ST, Dobson H, Bryant CE and Sheldon IM (2006) Expression and function of toll-like receptor 4 in the endometrial cells of the uterus. *Endocrinology* 147,562–570 [Epub 13 October 2005].
- Hertelendy F and Zakar T (2004) Regulation of myometrial smooth muscle functions. *Curr Pharm Des* 10,2499–2517.
- Hirst JJ, Parkington HC, Young IR, Palliser HK, Peri KG and Olson DM (2005) Delay of preterm birth in sheep by THG113.31, a prostaglandin F₂alpha receptor antagonist. *Am J Obstet Gynecol* 193,256–266.
- Hurd WW, Gibbs SG, Ventolini G, Horowitz GM and Guy SR (2005) Shortening increases spontaneous contractility in myometrium from pregnant women at term. *Am J Obstet Gynecol* 192,1295–1301.
- Kissler S, Doeinghaus K, Becker W and Wildt L (1995) Hysterosalpingoscintigraphic examination of the fallopian tube: a selective, unilateral transport mechanism. *Contracept Fertil Steril* 23,OC-286.
- Kissler S, Siebzehruebl E, Kohl J, Mueller A, Hamscho N, Gaetje R, Ahr A, Rody A and Kaufmann M (2004a) Uterine contractility and directed sperm transport assessed by hysterosalpingoscintigraphy (HSSG) and intrauterine pressure (IUP) measurement. *Acta Obstet Gynecol Scand* 83,369–374.
- Kissler S, Wildt L, Schmiedehausen K, Kohl J, Mueller A, Rody A, Ahr A, Kuwert T, Kaufmann M and Siebzehruebl E (2004b) Predictive value of impaired uterine transport function assessed by negative hysterosalpingoscintigraphy (HSSG). *Eur J Obstet Gynecol Reprod Biol* 113,204–208.
- Kunz G, Beil D, Deininger H, Wildt L and Leyendecker G (1996) The dynamics of rapid sperm transport through the female genital tract: evidence from vaginal sonography of uterine peristalsis and hysterosalpingoscintigraphy. *Hum Reprod* 11,627–632.
- Leyendecker G, Kunz G, Herbertz M, Beil D, Huppert P, Mall G, Kissler S, Noe M and Wildt L (2004) Uterine peristaltic activity and the development of endometriosis. *Ann N Y Acad Sci* 1034,338–355.
- Lyons EA, Taylor PJ, Zheng XH, Ballard G, Levi CS and Kredentser JV (1991) Characterization of subendometrial myometrial contractions throughout the menstrual cycle in normal fertile women. *Fertil Steril* 55,771–774.
- Maltaris T, Dragonas C, Hoffmann I, Mueller A, Schild RL, Schmidt W, Beckmann MW and Dittrich R (2005a) The extracorporeal perfusion of the swine uterus as an experimental model: the effect of tocolytic drugs. *Eur J Obstet Gynecol Reprod Biol* doi:10.1016/j.ejogrb.2005.07.026.
- Maltaris T, Scalera F, Schlembach D, Hoffmann I, Mueller A, Binder H, Goecke T, Hothorn T, Schild RL, Beckmann MW *et al.* (2005b) Increased uterine arterial pressure and contractility of perfused swine uterus after treatment with serum from pre-eclamptic women and endothelin-1. *Clin Sci (Lond)* 109,209–215.
- McNeilly AS, Robinson IC, Houston MJ and Howie PW (1983) Release of oxytocin and prolactin in response to suckling. *Br Med J (Clin Res Ed)* 286,257–259.
- Mueller A, Siemer J, Maltaris T, Binder H, Kaja H, Beckmann MW and Dittrich R (2005) The imbalance between vasoconstrictors and vasodilators in serum from pre-eclamptic women; results from perfused swine uteri using a complete digital measurement and data recording system. *Med Hypotheses Res* 2,543–551.
- Mueller A, Siemer J, Hoffmann I, Binder H, Beckmann MW and Dittrich R (2006) Role of estrogen and progesterone in the regulation of uterine peristalsis: results from perfused non-pregnant swine uteri. *Hum Reprod*; doi:10.1093/humrep/del056.
- Murphy MR, Checkley SA, Seckl JR and Lightman SL (1990) Naloxone inhibits oxytocin release at orgasm in man. *J Clin Endocrinol Metab* 71,1056–1058.
- Palliser HK, Hirst JJ, Ooi GT, Rice GE, Dellios NL, Escalona RM, Parkington HC and Young IR (2005) (Prostaglandin) E and F receptor expression and myometrial sensitivity at labor onset in the sheep. *Biol Reprod* 72,937–943.
- Ribeiro ML, Farina M, Aisemberg J and Franchi A (2003) Effects of *in vivo* administration of epidermal growth factor (EGF) on uterine contractility, prostaglandin production and timing of parturition in rats. *Reproduction* 126,459–468.
- Richter O, Wardelmann E, Dombrowski F, Schneider C, Kiel R, Wilhelm K, Schmolling J, Kupka M, van der Ven H and Krebs D (2000) Extracorporeal perfusion of the human uterus as an experimental model in gynaecology and reproductive medicine. *Hum Reprod* 15,1235–1240.
- Richter ON, Tschubel K, Schmolling J, Kupka M, Ulrich U and Wardelmann E (2003) Immunohistochemical reactivity of myometrial oxytocin receptor in extracorporeally perfused nonpregnant human uteri. *Arch Gynecol Obstet* 269,16–24.
- Richter ON, Kubler K, Schmolling J, Kupka M, Reinsberg J, Ulrich U, van der Ven H, Wardelmann E and van der Ven K (2004) Oxytocin receptor gene expression of estrogen-stimulated human myometrium in extracorporeally perfused non-pregnant uteri. *Mol Hum Reprod* 10,339–346.
- Richter ON, Bartz C, Dowaji J, Kupka M, Reinsberg J, Ulrich U and Rath W (2006) Contractile reactivity of human myometrium in isolated non-pregnant uteri. *Hum Reprod* 21,36–45 [Epub 9 September 2005].
- Robertson SA (2005) Seminal plasma and male factor signalling in the female reproductive tract. *Cell Tissue Res* 322,43–52.
- Ross RG, Sathishkumar K, Naik AK, Bawankule DU, Sarkar SN, Mishra SK and Prakash VR (2004) Mechanisms of lipopolysaccharide-induced changes in effects of contractile agonists on pregnant rat myometrium. *Am J Obstet Gynecol* 190,532–540.
- Russell JA and Leng G (1998) Sex, parturition and motherhood without oxytocin? *J Endocrinol* 157,343–359.
- Salonia A, Nappi RE, Pontillo M, Daverio R, Smeraldi A, Briganti A, Fabbri F, Zanni G, Rigatti P and Montorsi F (2005) Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. *Horm Behav* 47,164–169.
- Thornton S, Vatish M and Slater D (2001) Oxytocin antagonists: clinical and scientific considerations. *Exp Physiol* 86,297–302.
- Waclawik A, Rivero-Muller A, Blitek A, Kaczmarek MM, Brokken LJ, Watanabe K, Rahman NA and Ziecik AJ (2006) Molecular cloning and spatiotemporal expression of prostaglandin F synthase and microsomal prostaglandin E synthase-1 in porcine endometrium. *Endocrinology* 147,210–221 [Epub 13 October 2005].
- Whiteaker SS, Mirando MA, Becker WC and Peters DN (1995) Relationship between phosphoinositide hydrolysis and prostaglandin F_{2α} secretion *in vitro* from endometrium of cyclic pigs on day 15 postestrus. *Domest Anim Endocrinol* 12,95–104.
- Wijayagunawardane MP, Kodithumakku SP, Yamamoto D and Miyamoto A (2005) Vascular endothelial growth factor system in the cow oviduct: a possible involvement in the regulation of oviductal motility and embryo transport. *Mol Reprod Dev* 72,511–520.
- Wildt L, Kissler S, Licht P and Becker W (1998) Sperm transport in the human female genital tract and its modulation by oxytocin as assessed by hysterosalpingoscintigraphy, hysteronography, electrohystero-graphy and Doppler sonography. *Hum Reprod Update* 4,655–666.
- Willenburg KL, Knox RV and Kirkwood RN (2004) Effect of estrogen formulation and its site of deposition on serum PGFM concentrations, uterine contractility, and time of ovulation in artificially inseminated weaned sows. *Anim Reprod Sci* 80,147–156.
- Woodcock NA, Taylor CW and Thornton S (2004) Effect of an oxytocin receptor antagonist and rho kinase inhibitor on the [Ca²⁺]_i sensitivity of human myometrium. *Am J Obstet Gynecol* 190,222–228.
- Wu WX, Unno N, Ma XH and Pathanielsz PW (1999) Inhibition of prostaglandin production by nimesulide is accompanied by changes in expression of the cassette of uterine labor-related genes in pregnant sheep. *Endocrinology* 139,3096–3103.
- Ziganshin AU, Zefirova JT, Zefirova TP, Ziganshina LE, Hoyle CH and Burnstock G (2005) Potentiation of uterine effects of prostaglandin F₂(alpha) by adenosine 5'-triphosphate. *Obstet Gynecol* 105,1429–1436.

Submitted on February 14, 2006; resubmitted on March 17, 2006; accepted on March 24, 2006